Latest Breaking News On - Procare health iberia - Page 12 : comparemela.com
Financial News Media | Increasing R&D Studies to Develop Cancer Vaccines Attributed to Spike in Number of Cancer Patients
financialnewsmedia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialnewsmedia.com Daily Mail and Mail on Sunday newspapers.
BioVaxys y Procare Health, colaboración estrategica para el co-desarrollo y comercialización de vacunas terapéuticas contra cánceres ginecológicos de ovarios y de cervix
pmfarma.es - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmfarma.es Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU
Co-Development of Vaccines for Cervical Cancer and HPV
Right of First Refusal for US Marketing of Papilocare™
VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)
( BioVaxys ), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Procare Health Iberia, S.L., of Barcelona, Spain ( Procare Health ), a leading privately-held European pharmaceutical company, announced today that they have entered into a broad collaboration for the co-development, joint commercialization, and marketing of BioVaxys vaccines for ovarian cancer, cervical cancer, and human papilloma virus ( HPV ), and the right of first refusal for marketing by BioVaxys in the United States of Procare Health s vaginal gel product, Papilocare
Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy
Glenmede Investment Management Celebrates 5th Anniversary for Women in Leadership U.S. Equity Strategy Glenmede Investment Management LP (GIM), a privately owned, independent asset management firm, recently celebrated the five-year anniversary of its Glenmede Women in Leadership US Equity Strategy (Strategy). With more than $25.6 million in assets under management as of September 30, 2020, the strategy is a portfolio of large cap stocks, constructed with proprietary multi-factor models, based on a universe of securities with women in various positions of leadership. The strategys investment universe consists of equities of companies which meet an identified percentage of gender diversity in senior management and board membership. Since its inception in December 2015, Glenmedes Women in Leadership U.S. Equity Strategy increased its requirements by 5%. Currently, the strategy re